Xoma (XOMA) announced that based upon the FDA’s acceptance of Zevra Therapeutics’ (ZVRA) new drug application, or NDA, for arimoclomol, an orally-delivered, first-in-class therapy for Niemann-Pick disease type C, or NPC, Xoma will make a $1M milestone payment to LadRx. In June 2023, Xoma announced it had paid LadRx a $5M upfront payment plus a share of future event-based milestones to acquire a mid-single digit royalty on arimoclomol’s commercial sales and up to $52.6M, net, in potential milestone payments from Zevra. The transaction also included a mid-single-digit to mid-teens royalty rate on commercial sales of aldoxorubicin depending upon the indication, in addition to potential payments of up to $343M in development and commercial milestones from ImmunityBio.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on XOMA:
- FDA Acceptance of Zevra’s Arimoclomol NDA Filing for Niemann-Pick Disease Type C (NPC) Results in XOMA Making a $1 Million Milestone Payment to LadRx
- Xoma appoints Owen Hughes as CEO, Jack Wyszomierski as chairman
- XOMA Names Owen Hughes as Chief Executive Officer and Appoints Jack L. Wyszomierski as Chairman of the Board of Directors
- XOMA Announces Stock Repurchase Program of up to $50 Million
- Xoma board authorizes $50M stock repurchase program